Application of miRNA repressor in preparing drug for preventing and controlling myocardial infarction

A technology of myocardial infarction and inhibitors, applied in the field of biomedicine, can solve problems such as the unclear role of genetics

Active Publication Date: 2018-01-26
SUZHOU UNIV
View PDF2 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, AMI is a disease affected by multiple genetic and environmental factors, and the role of genetics in the pathogenesis of AMI is still unclear.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of miRNA repressor in preparing drug for preventing and controlling myocardial infarction
  • Application of miRNA repressor in preparing drug for preventing and controlling myocardial infarction
  • Application of miRNA repressor in preparing drug for preventing and controlling myocardial infarction

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0033] Example 1: Myocardial injection of miR-9 inhibitor preparations effectively reduces cardiac miR-9 content

[0034] 1. Inject the miR-9 inhibitor into the myocardium in vivo and verify the expression level of cardiac miR-9

[0035]About 25 g of C57BL / 6J male mice were selected as the experimental subjects, and the mixed preparation of miR-9 inhibitor and Dharmafect Duo was injected at two sites in the left ventricle, and antagomir NC was used as a negative control. The mixed preparation injected per mouse included 60 μg miR-9 inhibitor and 8 μl Dharmafect Duo;

[0036] 2. Detection of cardiac miR-9 expression level by QPCR

[0037] According to the routine cardiac total RNA extraction, inversion and QPCR, 4 replicate wells were set up for each sample, the reaction system was 10 μl, and U6 was used as an internal reference;

[0038] See attached figure 1 , is the expression level map of myocardial miR-9 detected by QPCR. It can be seen that the administration of miR-9 ...

Embodiment 2

[0039] Example 2: miR-9 inhibitor effectively improves left ventricular ejection fraction (ejection fraction, EF, %) and left ventricular fractional shortening (fractional shortening, FS, %) after myocardial infarction

[0040] 1. Establishment of myocardial infarction model in mice

[0041] About 25 g C57BL / 6J male mice were selected as the experimental subjects, and the myocardial infarction model was established by ligation of the left anterior descending coronary artery. After intraperitoneal injection of anesthesia, orotracheal intubation, connected to an air ventilator, respiratory rate 110 times / min, tidal volume 3ml, breath-to-breath ratio 1:1.3. In the right decubitus position, the outer skin was incised through the left thoracic longitudinal incision, the pectoralis major muscle was peeled off, the chest was opened through the third and fourth intercostal transverse incisions, the heart was exposed, and the pericardium was torn off with tweezers. The left coronary a...

Embodiment 3

[0045] Example 3: miR-9 inhibitor significantly reduces myocardial infarction size

[0046] 1. Establishment of mouse myocardial infarction model: same as Example 2;

[0047] 2. In vivo myocardial injection of miR-9 inhibitor: same as Example 1;

[0048] 3. Masson staining: the mice were killed 7 days after the operation, and the left ventricle tissue was taken for cardiac tissue staining to observe the therapeutic effect. Follow the routine Masson staining procedure, observe and take pictures under an ordinary light microscope. The image analysis software Image J was used to analyze the area of ​​each part, and the area of ​​myocardial infarction / heart area was calculated;

[0049] See attached Figure 4 , attached Figure 5 , the infarct area of ​​each group was observed 7 days after myocardial infarction by Masson staining ( Figure 4 A), it was found that the size of myocardial infarction in the miR-9 suppressed subgroup was significantly lower than that in the contro...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to an application of a miRNA repressor in preparing a drug for preventing and controlling myocardial infarction. The invention firstly utilizes a miRNA-9 repressor to treat myocardial infarction. The embodiment has the following extraordinary technical effects: the direct injection of the miR-9 repressor through cardiac muscle is capable of obviously reducing the expression of heart miR-9, the miR-9 repressor injected into the peripheral area of acute myocardial infarction is capable of effectively improving the heart function after myocardial infarction and reducing themyocardial infarction area, inflammation level and ROS accumulation degree in the peripheral area of acute myocardial infarction and the miRNA repressor can be used for preventing and treating the myocardial infarction.

Description

technical field [0001] The invention belongs to the field of biomedicine, and specifically relates to the application of a miRNA inhibitor in the preparation of drugs for preventing and treating myocardial infarction. Background technique [0002] Myocardial infarction is a cardiovascular disease that seriously endangers human health. With the continuous improvement of people's living standards in our country, the incidence of ischemic myocardial infarction is also increasing. Ischemic myocardial infarction can lead to myocardial cell necrosis and scar formation, thereby affecting cardiac function, especially acute myocardial infarction (AMI), the most serious clinical type of coronary atherosclerotic heart disease. Most of the current drug or device treatments can only relieve the symptoms, but they cannot reverse the damage to the heart tissue. Although heart transplantation can completely improve the state of the heart, it is difficult to be widely used clinically due to...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/7105A61P9/10
Inventor 陈维倩沈振亚肖亦敏
Owner SUZHOU UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap